Host-pathogen interactions of emerging zoonotic viruses: bats, humans and filoviruses.
Journal article
Hood G. and Carroll M., (2024), Current opinion in virology
rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l'essai proches).
Journal article
Watson CH. et al, (2024), BMC medicine, 22
Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials
Journal article
Chan XHS. et al, (2024), The Lancet Microbe, 101002 - 101002
Performance of an envelope glycoprotein-based multiplex immunoassay for Ebola virus antibody detection in a cohort of Ebola virus disease survivors.
Journal article
Roe MD. et al, (2024), Journal of virological methods, 331
Obesity differs from diabetes mellitus in antibody and T-cell responses post-COVID-19 recovery
Journal article
Ali M. et al, (2024), Clinical and Experimental Immunology, 218, 78 - 92
Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.
Journal article
Lim YJ. et al, (2024), British journal of haematology, 205, 440 - 451
Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study
Journal article
Jackson S. et al, (2024), The Lancet Microbe, 5, 655 - 668
Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
Journal article
Goodyear CS. et al, (2024), The Lancet. Rheumatology, 6, e339 - e351
Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2
Journal article
Cornish K. et al, (2024), Open Biology, 14
Serological evidence of zoonotic filovirus exposure among bushmeat hunters in Guinea.
Journal article
Akoi Boré J. et al, (2024), Nature communications, 15
Nipah Virus Therapeutics: A Systematic Review to Support Prioritisation for Clinical Trials
Preprint
Chan XHS. et al, (2024)
Direct enhancement of viral neutralising antibody potency by the complement system: a largely forgotten phenomenon.
Journal article
Mellors J. and Carroll M., (2024), Cellular and molecular life sciences : CMLS, 81
Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients
Journal article
Murray SM. et al, (2024), Journal of Hepatology, 80, 109 - 123
Serum HCoV-spike specific antibodies do not protect against subsequent SARS-CoV-2 infection in children and adolescents
Journal article
Ratcliffe H. et al, (2023), iScience, 26, 108500 - 108500
CD4+ and CD8+ T cells and antibodies are associated with protection against Delta vaccine breakthrough infection: a nested case-control study within the PITCH study
Journal article
Neale I. et al, (2023), mBio, 14
A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2
Journal article
Wilkinson T. et al, (2023), ERJ Open Research, 9, 00249 - 2023
Cellular immunity to SARS-CoV-2 following intrafamilial exposure in seronegative family members
Journal article
Jay C. et al, (2023), Frontiers in Immunology, 14
Omicron infection following vaccination enhances a broad spectrum of immune responses dependent on infection history
Journal article
Hornsby H. et al, (2023), Nature Communications, 14
Corrigendum: Inhibition of phosphodiesterase 12 results in antiviral activity against several RNA viruses including SARS-CoV-2.
Journal article
Thursz M. et al, (2023), The Journal of general virology, 104
Establishing SARS-CoV-2 membrane protein-specific antibodies as a valuable serological target via high-content microscopy.
Journal article
Williams DM. et al, (2023), iScience, 26